PRAX News and Press, Praxis Precision Medicines Inc. From 03/26/24

2024-03-26 13:34:38 ET Summary Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportuni...

A look at the top 10 most actives in the United States C3is Inc. (CISS) rose 50.9% to $0.0531 on volume of 188,520,681 shares OpGen Inc. (OPGN) rose 64.8% to $0.783 on volume of 46,448,042 shares KULR Technology Group Inc. (KULR) rose 26.2% to $0.4102 on volume of 30,163,025 shares Tesl...

2024-03-26 08:54:38 ET Praxis Precision Medicines ( NASDAQ: PRAX ) added ~20% premarket Tuesday after the company said its experimental oral therapy PRAX-628 led to a 100% complete response in a mid-stage trial for patients with photo paroxysmal response, a characteristic of epi...

In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prior dose escalation study and PK analysis confirmed therapeutic exposures P...

Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Praxis Pr...

2024-03-06 13:06:02 ET More on Praxis Precision Medicines Praxis Precision Medicines falls after pricing of $150M equity offering Read the full article on Seeking Alpha For further details see: Praxis Precision Medicines GAAP EPS of -$2.97 misses by $0.92, revenu...

2024-03-05 11:12:10 ET More on Praxis Precision Medicines Biggest stock movers today: Hertz Global, Crypto-linked stocks, Southwestern Energy, and more Praxis Precision Medicines falls after pricing of $150M equity offering Seeking Alpha’s Quant Rating on Prax...

Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024 Topline results from the PRAX-628...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...